SCHEMBL5609146

SCHEMBL5609146

FC(F)(F)C(S)Cc1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ACE P12821 4/20 0.53
EPHX1 P07099 1/20 0.44
ANPEP P15144 1/20 0.43
ECE1 P42892 1/20 0.43
CPA1 P15085 1/20 0.42
SLC6A2 P23975 3/20 0.41
TAAR1 Q96RJ0 3/20 0.41
SLC6A4 P31645 2/20 0.41
SLC6A3 Q01959 2/20 0.41
MAOA P21397 1/20 0.41
SIGMAR1 Q99720 1/20 0.41
CYP2A6 P11509 1/20 0.41
ADORA2A P29274 1/20 0.41
ADORA1 P30542 1/20 0.41
CYP1A2 P05177 1/20 0.40
CPA3 P15088 1/20 0.39
FOLH1 Q04609 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3238111 0.76 EPHX1 (0.48) ACEEPHX1ANPEPCPA1SLC6A2
SCHEMBL16034061 0.74 EPHX1 (0.46) ACEEPHX1ANPEPCPA1SLC6A2
SCHEMBL5609931 0.73 EPHX1 (0.50) EPHX1ANPEPSLC6A2TAAR1SLC6A4
SCHEMBL10693279 0.73 EPHX1 (0.44) ACEEPHX1ANPEPCPA1SLC6A2
SCHEMBL5609280 0.73 CPA1 (0.46) ACEEPHX1ANPEPCPA1SLC6A2
SCHEMBL838906 0.73 MEN1 (0.46) ACEEPHX1CPA1SLC6A2TAAR1
SCHEMBL7256073 0.73 EPHX1 (0.44) ACEEPHX1ANPEPCPA1SLC6A2
SCHEMBL2059538 0.73 EPHX1 (0.44) ACEEPHX1ANPEPCPA1SLC6A2
SCHEMBL6380241 0.73 EPHX1 (0.56) EPHX1ANPEPSLC6A2TAAR1SLC6A4
SCHEMBL638408 0.73 EPHX1 (0.56) EPHX1ANPEPSLC6A2TAAR1SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7199139-B2 Medicinal compositions containing diuretic and insulin resistance-improving agent SANKYO COMPANY, LIMITED (JP) 2007-04-03 US disclosed
EP-1354602-B1 MEDICINAL COMPOSITIONS CONTAINING DIURETIC AND INSULIN RESISTANCE-IMPROVING AGENT SANKYO CO (JP) 2006-10-04 EP disclosed
EP-1695716-A2 Medicinal compositions containing diuretics and insulin sensitizers Sankyo Company, Limited (JP) 2006-08-30 EP disclosed
US-20050288339-A1 Medicinal compositions containing diuretic and insulin resistance-improving agent SANKYO COMPANY, LIMITED (JP) 2005-12-29 US disclosed
US-20040053974-A1 Medicinal compositions containing diuretic and insulin resistance-improving agent SANKYO COMPANY, LIMITED (JP) 2004-03-18 US disclosed
US-20040002512-A1 Alpha-substituted carboxylic acid derivatives SANKYO COMPANY, LIMITED (JP) 2004-01-01 US disclosed
EP-1354602-A1 MEDICINAL COMPOSITIONS CONTAINING DIURETIC AND INSULIN RESISTANCE-IMPROVING AGENT Sankyo Company, Limited (JP) 2003-10-22 EP disclosed
US-6596751-B2 An insulin resistance improving agent, hypoglycemic agent, immunoregulatory agent, aldose reductase inhibitor, 5-lipoxygenase inhibitor, peroxidized lipid production suppressor, PPAR. activator, leukotriene antagonist, adipose SANKYO COMPANY LIMITED (JP) 2003-07-22 US disclosed
US-20030069294-A1 Alpha-substituted carboxylic acid derivatives SANKYO COMPANY, LIMITED (JP) 2003-04-10 US disclosed
EP-1167357-A1 ALPHA-SUBSTITUTED CARBOXYLIC ACID DERIVATIVES Sankyo Company, Limited (JP) 2002-01-02 EP disclosed
US-6191297-B1 HYDROSILATION OF FUNCTIONALLIZED ALLYL COMPOUNDS, E.G. ALLYL CHLORIDE, BY HYDROGEN SILANES, E.G. DICHLOROMETHYLSILANE, USING A CATALYST OF A COMPLEX OF PLATINUM AND ONE OR MORE SULFUR-CONTAINING LIGANDS; EFFICIENCY DEGUSSA-HULS AG (DE) 2001-02-20 US disclosed
EP-0645355-B1 Method for the preparation of trifluoroethyl sulphur compounds from thiolates and 1-chloro-2,2,2-trifluoroethane SOLVAY (BE) 2000-03-22 EP disclosed
CN-1241570-A New process for preparation of organosilanes functionalised in the 3-position DEGUSSA (DE) 2000-01-19 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002512-A1 Alpha-substituted carboxylic acid derivatives SLC5A1, SLC2A1, GPR119 ACE 2201/4885EPHX1 2395/4885ANPEP 3250/4885
US-20030069294-A1 Alpha-substituted carboxylic acid derivatives SLC5A1, SLC2A1, GPR119 ACE 2201/4885EPHX1 2395/4885ANPEP 3250/4885
US-20040053974-A1 Medicinal compositions containing diuretic and insulin resistance-improving agent GPR119, INSR, IRS1 ACE 170/4885EPHX1 2426/4885ANPEP 1993/4885
US-20050288339-A1 Medicinal compositions containing diuretic and insulin resistance-improving agent GPR119, INSR, IRS1 ACE 170/4885EPHX1 2426/4885ANPEP 1993/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.